UniSa - IRIS Institutional Research Information System

MASARONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.917
NA - Nord America 5.843
EU - Europa 2.270
SA - Sud America 793
Continente sconosciuto - Info sul continente non disponibili 278
AF - Africa 128
OC - Oceania 6
Totale 18.235
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 5.781
US - Stati Uniti d'America 5.652
SG - Singapore 1.340
IT - Italia 952
CN - Cina 663
BR - Brasile 608
VN - Vietnam 476
RU - Federazione Russa 281
UA - Ucraina 192
DE - Germania 168
FR - Francia 154
TR - Turchia 130
IE - Irlanda 126
KR - Corea 111
BD - Bangladesh 108
CA - Canada 84
GB - Regno Unito 80
AR - Argentina 77
SE - Svezia 73
FI - Finlandia 65
IN - India 63
MX - Messico 50
ZA - Sudafrica 43
JP - Giappone 37
IQ - Iraq 36
NL - Olanda 34
EC - Ecuador 33
ID - Indonesia 33
DK - Danimarca 27
PL - Polonia 24
CO - Colombia 22
VE - Venezuela 22
PK - Pakistan 21
ES - Italia 19
AT - Austria 17
UZ - Uzbekistan 15
MA - Marocco 14
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
PY - Paraguay 12
EG - Egitto 11
HN - Honduras 11
JM - Giamaica 11
AE - Emirati Arabi Uniti 10
CR - Costa Rica 10
MY - Malesia 9
PS - Palestinian Territory 9
KE - Kenya 8
PH - Filippine 8
AL - Albania 7
GR - Grecia 7
KZ - Kazakistan 7
LT - Lituania 7
TN - Tunisia 7
AZ - Azerbaigian 6
DZ - Algeria 6
PE - Perù 6
SN - Senegal 6
EU - Europa 5
RO - Romania 5
AU - Australia 4
CG - Congo 4
CL - Cile 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
IL - Israele 4
JO - Giordania 4
NO - Norvegia 4
OM - Oman 4
UG - Uganda 4
AO - Angola 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CI - Costa d'Avorio 3
ET - Etiopia 3
LY - Libia 3
NI - Nicaragua 3
NP - Nepal 3
PT - Portogallo 3
QA - Qatar 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BB - Barbados 2
CH - Svizzera 2
GE - Georgia 2
GY - Guiana 2
IR - Iran 2
LB - Libano 2
LC - Santa Lucia 2
LV - Lettonia 2
MW - Malawi 2
RS - Serbia 2
TH - Thailandia 2
TW - Taiwan 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BS - Bahamas 1
Totale 17.934
Salva come PNG Salva come JPEG
Città #
Hong Kong 5.770
Ann Arbor 778
Singapore 657
San Jose 656
Ashburn 367
Chandler 361
Princeton 344
Milan 336
Woodbridge 334
Jacksonville 263
Dallas 247
Council Bluffs 224
Beijing 180
Houston 180
The Dalles 140
Dublin 123
Ho Chi Minh City 123
Lauterbourg 108
Dong Ket 106
Izmir 106
Wilmington 102
Los Angeles 91
Hanoi 87
Rome 84
Moscow 74
Nanjing 73
New York 66
Andover 63
Santa Clara 61
São Paulo 61
Munich 56
Naples 52
Boardman 45
Pellezzano 44
Tokyo 35
Memphis 32
Salerno 29
Fairfield 27
Figino 27
Johannesburg 26
Redwood City 26
Changsha 24
Mexico City 24
Montreal 24
Norwalk 24
Brooklyn 23
Hebei 23
Frankfurt am Main 22
Shenyang 22
Turin 22
Turku 22
Columbus 21
Haiphong 21
Rio de Janeiro 21
Warsaw 20
Washington 20
Orem 19
Amsterdam 18
Chennai 18
Chicago 18
Da Nang 18
Denver 18
London 18
Stockholm 18
Belo Horizonte 17
Jinan 17
Nanchang 17
Dearborn 16
Dhaka 16
Phoenix 16
Atlanta 15
Tashkent 15
Jiaxing 14
Nuremberg 14
Seattle 14
Baghdad 12
Brasília 12
Curitiba 12
Guayaquil 12
Helsinki 12
Manchester 12
Tianjin 12
Copenhagen 11
Guangzhou 11
Toronto 11
Caracas 10
Fisciano 10
Jinju 10
Nürnberg 10
Poplar 10
San Diego 10
Boston 9
Buffalo 9
City of London 9
Erbil 9
Maletto 9
Ninh Bình 9
Ottawa 9
Pontecagnano 9
San José 9
Totale 13.471
Salva come PNG Salva come JPEG
Nome #
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 774
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 769
Non Alcoholic Fatty Liver: Epidemiology and Natural History 633
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 610
Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study 502
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 443
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 400
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 381
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 348
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 324
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 322
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 314
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 305
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 284
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 266
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 213
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 211
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 194
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 193
The diagnostic conundrum in non-alcoholic fatty liver disease 191
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 184
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 160
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 159
Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study 158
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 155
Coeliac disease and C virus-related chronic hepatitis: a non association 155
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 155
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 152
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 152
Alcoholic Liver Disease and Hepatitis C Chronic Infection 146
Epidemiology and Natural History of Alcoholic Liver Disease 144
Adiponectin in hepatology 144
Pharmacotherapy of alcoholic liver disease in clinical practice 143
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus 136
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 136
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 134
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 134
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 133
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease 132
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 131
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 131
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 129
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 127
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 127
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 124
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 124
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 123
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 122
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 120
Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study 118
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 116
Efficacy and Safety of a Polysaccharide-Based Natural Substance Complex in the Treatment of Obesity and Other Metabolic Syndrome Components: A Systematic Review 114
Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno 114
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 113
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 113
Viral hepatitis: Milestones, unresolved issues, and future goals 113
Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver 112
Lung ultrasound for diagnosis of pneumonia in emergency department 111
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 111
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy 110
Metabolic associated steatotic liver disease in renal transplant recipients: a retrospective cohort study 109
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 107
Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: A pilot study 107
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 107
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 105
HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era 105
Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease 104
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 104
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 103
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 103
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 102
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. 101
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 101
Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study 99
Real‐Life Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Infected Patients with Chronic Kidney Disease 99
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 98
Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis 98
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. 95
Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis 94
NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome 94
Gut-Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers 93
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. 93
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System 93
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study 92
HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 91
P. 253 Rapid virological response in genotype 1b patients treated with peginterferon plus ribavirin: evidence for a significant sustained virological response (SVR) after 24 weeks of therapy in peg-interferon-alpha-2a treated patients 88
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 88
HCV point-of-care screening program and treatment options for people who use drugs in a metropolitan area of Southern Italy 88
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. 86
A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 85
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 84
Corrigendum to “Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)” [Dig Liver Dis 54 (2022) 170–182, (S1590865821002140), (10.1016/j.dld.2021.04.029)] 84
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 84
Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study 83
Artificial Intelligence and liver: Opportunities and barriers 83
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 83
Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy 81
Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle? 78
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention 74
Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience 69
Totale 16.727
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.008
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.008
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022597 0 0 9 7 10 10 22 31 83 82 80 263
2022/2023918 102 72 54 110 99 189 3 67 135 5 60 22
2023/2024515 35 49 36 24 39 100 26 31 9 19 35 112
2024/20251.585 32 29 23 53 106 165 272 150 284 106 189 176
2025/202611.207 695 2.891 2.923 522 776 366 927 219 392 606 237 653
2026/2027414 206 206 2 0 0 0 0 0 0 0 0 0
Totale 18.235